

## Board director in Egetis Therapeutics acquires shares

**Stockholm, Sweden, May 31, 2023. Egetis Therapeutics AB (publ) (STO: EGTX) (the "Company") today announced that Mats Blom, Board director, has acquired 200,000 additional shares in the Company on May 31, 2023. Mats Blom's total holding in the Company now amounts to 3,134,762 shares.**

**For further information, please contact:**

---

Nicklas Westerholm, CEO  
+46 (0) 733 542 062  
nicklas.westerholm@egetis.com

Karl Hård, Head of Investor Relations & Business Development  
+46 (0) 733 011 944  
karl.hard@egetis.com

### About Egetis Therapeutics

---

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment. The Company's lead drug candidate *Emcitate* is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) *Emcitate* has shown highly significant and clinically relevant results on serum thyroid hormone T3 levels and secondary clinical endpoints. As a result of regulatory interaction Egetis intends to submit a marketing authorisation application (MAA) for *Emcitate* to the European Medicines Agency (EMA) during the early autumn of 2023 based on existing clinical data.

After a dialogue with the FDA, Egetis will conduct a small randomized, placebo-controlled study in 16 patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis intends to submit a new drug application (NDA) in the US for *Emcitate* in the fourth quarter of 2023 under the Fast-Track Designation granted by FDA.

*Emcitate* is currently being investigated in the Triac Trial II, a Phase II/III study in very young MCT8 deficiency patients (<30 months of age) exploring potential disease modifying effects of early intervention from a neurocognitive and neurodevelopmental perspective. The recruitment target was achieved in the second quarter 2022 and 22 patients have been included in the study. Results are expected in mid 2024 and are expected to be submitted post-approval to regulatory authorities shortly thereafter.

*Emcitate* holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. *Emcitate* has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.

The drug candidate *Aladote* is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase I/III study with the purpose of applying for market approval in the US and Europe for *Aladote* has been finalized after completed interactions with FDA, EMA and MHRA and study start is planned during 2023. *Aladote* has been granted ODD in the US and in the EU.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see [www.egetis.com](http://www.egetis.com)



**PRESS RELEASE**  
31 May 2023 14:30:00 CEST

## **Attachments**

---

[Board director in Egetis Therapeutics acquires shares](#)